Compare Global X MSCI Argentina ETF (ARGT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X MSCI Argentina ETF vs Mesoblast Limited — how do they compare? Global X MSCI Argentina ETF trades at $92.45, while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Global X MSCI Argentina ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| ARGT | MESO | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $102.94 | $20.96 |
52-Week Low | $67.55 | $12.88 |
Market Cap | — | $2.16B |
Enterprise Value | — | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARGT trades at $92.96, up 0.43% with a bearish technical signal from moving averages. The ETF shows neutral oscillators with RSI at 44.95. Recent Seeking Alpha analysis (June 18, 2026) highlights a 28% upside potential as Argentina's economic reforms progress, with the fund trading at 12.5x earnings below its post-Milei average.
The outlook suggests potential re-rating to 14-18x earnings could yield 12-44% upside, supported by Argentina's improving monetary backdrop. Key risks include country-specific volatility and concentrated holdings in MercadoLibre. Institutional interest is growing with Stanley Druckenmiller's recent position accumulation.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X MSCI Argentina ETF
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
